Unglaublich: BridgeBio mit 75% in 5 Wochen

https://www.stonkmoon.com/news/BBIO/84964eee8c5a7c671da6dfc5b4e0e715  

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)


https://newsfilter.io/a/963375e4a9c5a76026b14ff7972dddf9  

https://www.nasdaq.com/de/market-activity/stocks/bbio/real-time  

 

https://www.tipranks.com/news/blurbs/...k.pro&utm_medium=referral  

https://www.fiercebiotech.com/biotech/...ys-second-round-layoffs-year  

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years BridgeBio Pharma, Inc.  

https://www.globenewswire.com/news-release/2022/...vestor-Events.html  

https://www.chartmill.com/news/BBIO/...ne-therapy-for-canavan-disease  

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers


https://www.chartmill.com/stock/quote/BBIO/...ampaign=social_tracking  

https://www.google.com/maps/place/...0!8m2!3d37.4484039!4d-122.160524

Erst mal den Zaun streichen, dann kann man sich auch um die Post kümmern.

Auch mal die Google Bewertung lesen.  

BridgeBio Pharma hat satte 299,2 Millionen US-Dollar eingesackt, um seine Pipeline für genetische
Krankheiten voranzutreiben, die mehr als ein Dutzend Vermögenswerte in der präklinischen und
klinischen Entwicklung umfasst.

BridgeBio wurde 2015 gegründet und arbeitet in mehreren therapeutischen Bereichen und zielt auf
eine breite Palette von Indikationen ab, darunter Transthyretin-Amyloidose (ATTR), Pantothenatkinase-assoziierte
Neurodegeneration (PKAN), Gorlin-Syndrom und häufige Basalzellkarzinome, Netherton-Syndrom,
Molybdän-Cofaktor Mangeltyp A und FGFR-, SHP-2- und K-RAS-gesteuerte Krebsarten, um nur einige zu nennen.

KKR und Viking Global Investors führten die Runde an, und Sequoia Capital beteiligte sich neben den
bestehenden Geldgebern von BridgeBio, Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital
und Hercules Capital.

https://www.fiercebiotech.com/biotech/...ead-299m-round-for-bridgebio

Viele Dollars verbrannt !
 

https://flashalert.me/...pterin-for-the-Treatment-of-MoCD-Type-A.html  

https://www.stocktitan.net/news/BBIO/...ial-results-db4tssg7dv6f.html  

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A  

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) – SVB Leerink issued their Q1 2023 earnings per share (EPS) estimates for BridgeBio Pharma in a report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar forecasts that the company will post earnings of ($0.92) per share for the quarter. SVB Leerink currently has a “Outperform” rating and a $19.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.89) per share. SVB Leerink also issued estimates for BridgeBio Pharma’s FY2024 earnings at ($2.19) EPS.

https://zolmax.com/investing/...2023-earnings-nasdaqbbio/8448697.html  

https://www.nasdaq.com/de/market-activity/stocks/bbio/real-time  

BlackRock Increases Position in BridgeBio Pharma (BBIO)
February 01, 2023 — 06:12 am EST
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 9.83MM shares of BridgeBio Pharma Inc (BBIO). This represents 6.6% of the company.

In their previous filing dated February 3, 2022 they reported 9.28MM shares and 6.30% of the company, an increase in shares of 6.02% and an increase in total ownership of 0.30% (calculated as current - previous percent ownership).  

 

https://beststocks.com/...bio-pharma-inc-is-owned-by-russell-investm/  

Ist 12 ne Hürde? Wenn nein, dann wird das Jahreshoch angegriffen....

https://www.nasdaq.com/de/market-activity/stocks/bbio/real-time  

 

https://www.nasdaq.com/de/market-activity/stocks/bbio/earnings  

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
March 06, 2023 07:00 ET | Source: BridgeBio Pharma, Inc.